The Latest

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    ADARx Pharmaceuticals outlined terms for an offering that, at its midpoint, would value the RNA drug developer at around $1.8 billion.

    Updated 5 hours ago
  • DR. meeting with client
    Image attribution tooltip
    Permission granted by Walgreens
    Image attribution tooltip
    Sponsored by Walgreens Specialty Pharmacy

    Behind the outcomes: How whole-patient support is reshaping oncology care

    As oncology care grows personalized and home-based, support around treatment becomes as vital as treatment.

  • An illustration of the collapse of a stock price
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Xenon shares fall following depression trial pause

    The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug

    Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.

  • A street sign for Wall Street in front of the facade of the New York Stock Exchange.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Electra amasses $350M in biotech’s latest big IPO

    Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to BioPharma Dive data.

  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Lisata deal propels Marea’s drug pipeline to Wall Street

    Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.

  • A photo of Wall Street in New York City in 2022.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    North Immunology joins biotech reverse merger boom with Aethlon deal

    Armed with $180 million and a dual-acting antibody for eczema, the startup is capitalizing on a change in sentiment that’s led to a sudden spike in reverse merger deals.

  • The exterior of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Roche, Dualitas team up to find bispecific drugs for immune diseases

    Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments. 

  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis to pay $125M for blood-brain barrier crossing platform

    Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class” potential.

  • A low-angle, full shot of the Nasdaq MarketSite building in Times Square under a bright, overcast sky, featuring a large, curved blue digital billboard. The billboard displays a welcome message reading "Nasdaq Welcomes Faeth Therapeutics, June 23, 2026," alongside the Faeth logo and "FTH Nasdaq Listed."
    Image attribution tooltip
    Permission granted by Faeth Therapeutics
    Image attribution tooltip
    Deep Dive

    A booming business on Wall Street would love more biotechs to quietly die

    Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality shell companies to meet the demand.

  • Close-up view of the Novo Nordisk logo mounted on the exterior wall of a building. The logo features a stylized blue Apis bull with a sun disk above its head, symbolizing the company's identity. The background shows a tan brick wall and part of a leafless tree in the foreground under a clear blue sky."
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Obesity drugs

    Novo partners with Orbis, deepening investment in oral peptide drugs

    The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.

  • An illustration of a cancerous tumor inside the lungs
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight

    The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.

  • FDA magnifying glass
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    FDA launches pilot program to speed up early US drug research

    First teased in June and formally announced Tuesday as part of “Operation Trialblazer,” the program will partner drugmakers with research institutions to more quickly bring medicines into human testing. 

    FDA
  • OpenAI ChatGPT and Anthropic Claude application icons shown on screen.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novo looks to Anthropic’s AI models to ‘supercharge’ drug development

    The Danish drugmaker will use Claude Science as part of a goal to become "the world’s most AI-driven healthcare company."

  • eye
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Sling banks $123M for an experimental thyroid eye disease pill

    A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the first oral alternative to approved injectables like Amgen's Tepezza and Viridian's Lumvoa.

  • A technician wearing a blue mask works in a laboratory.
    Image attribution tooltip
    Kevin Frayer via Getty Images
    Image attribution tooltip
    China competition

    Drugs from China are reshaping biotech. Track the licensing deals here.

    GSK has signed its fifth licensing deal with a China-based drugmaker since the start of 2025, agreeing to pay Chimagen Biosciences up to $750 million for a three-pronged T-cell engager for multiple myeloma.

    Updated Sept. 15, 2026
  • An illustration of neuron cells in abstract dark space.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Skyhawk racks up more support for Huntington’s drug

    The Fidelity-backed biotech now has 15-month data from a small study of its RNA-splicing therapy.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA clears first generic radioligand drug; Sionna turns to layoffs

    A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.

  • An illustration of two immune checkpoint proteins binding
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results

    As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.

  • An illustration of a gene being inserted into a helix strand.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing

    Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.

  • A photo of the packaging for the spinal muscular atrophy drug Isemblyd.
    Image attribution tooltip
    Courtesy of Scholar Rock
    Image attribution tooltip

    Scholar Rock SMA drug approved by FDA

    Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in clinical testing, helped improve motor function in people on standard therapies. 

    FDA
  • A double exposure image of a glass flask in a laboratory with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree

    RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin Group.

  • A stylized illustration of test tubes in front of a red line on a chart going up and to the right.
    Image attribution tooltip
    Adeline Kon/BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Emerging biotech

    Biotech startups are built on venture capital. Track funding rounds here.

    Six biotechs raised over $700 million in combined venture funding this week, though two of those companies — Solstice Oncology and Encoded Therapeutics — accounted for the bulk of the total.

    Updated Sept. 11, 2026
  • Gloved workers supervise rows of glass bottles on a pharmaceutical production line.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    mRNA cancer vaccines’ biggest barriers to market

    Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

  • A sign reads "AstraZeneca" with the company logo on an all-glass-grided building facade.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    AstraZeneca’s newly approved pill fails frontline breast cancer study

    Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year. 

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use

    Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.